Is S3V Vascular Technologies planning an IPO?

No confirmed IPO plans have been publicly announced by S3V Vascular Technologies as of the available information. The company remains unlisted and privately held.

Where is S3V Vascular Technologies based?

S3V Vascular Technologies is headquartered in Mysuru, Karnataka, and was incorporated in 2011 under Karnataka jurisdiction (CIN: U33112KA2011PLC059915).

How do I buy S3V Vascular Technologies Limited unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for S3V Vascular Technologies Limited?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell S3V Vascular Technologies Limited shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

S3V Vascular Technologies Limited Unlisted Share Price | Buy S3V Vascular Technologies Limited Pre-IPO Shares — wisefolio

Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Talk to us

S3V Vascular Technologies Limited Unlisted Share Price | Buy S3V Vascular Technologies Limited Pre-IPO Shares — wisefolio | wisefolio

Investment Thesis

S3V Vascular Technologies Limited is an early-stage MedTech company developing cardiovascular devices in a strategically important and high-margin sector. The company benefits from India's strong push to reduce import dependence in medical devices and the large domestic cardiovascular disease burden. However, regulatory approval timelines, capital requirements, and competition from multinational players present significant challenges before meaningful revenue scale can be achieved.

Pros

Medical devices for cardiovascular and critical-care applications — high-value niche; revenue ₹16 Cr (FY2024-25); ₹15.2 Cr (FY2023-24) — steady growth; Hootagalli Industrial Area, Mysuru — established manufacturing zone.
81 employees (Aug 2025); 14+ years since 2011; NIC 33112 — instruments and appliances for medical/surgical/dental/veterinary practice; Make-in-India medical devices aligned with government PLI schemes.
Mysuru, Karnataka — India's emerging medical device manufacturing hub; proximity to Bengaluru's healthcare ecosystem.

Cons

Revenue ₹16 Cr — small scale for cardiovascular medical devices; competition from global players (Medtronic, Abbott, Edwards Lifesciences) and larger Indian MedTech firms.
U-prefix (unlisted) — no secondary market; no ISIN confirmed for public trading; limited investor visibility.
Cardiovascular medical devices require CDSCO approval, clinical trials, and international certifications (ISO 13485, CE, FDA) — high regulatory burden.
Nagaradagadde family management dominance — key-man risk; 81 employees suggests limited R&D bandwidth for complex vascular devices.

Business Segments

Cardiovascular & Critical-Care Medical Devices

Development and manufacturing of advanced medical devices for cardiovascular and critical-care applications; NIC 33112; Hootagalli Industrial Area, Mysuru 570018, Karnataka.

Revenue Model

Revenue generated through sale of cardiovascular and critical-care medical devices to hospitals, catheterisation laboratories, and interventional cardiologists in India, with potential for export to regulated and semi-regulated markets.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds9

Growth Plans

India's Production Linked Incentive (PLI) scheme for medical devices supports domestic manufacturers with financial incentives

Government mandate for domestic procurement preference in public hospitals benefits local manufacturers

Large underserved cardiovascular disease burden in India creates significant addressable market for cost-effective indigenous devices

Industry Tailwinds

Recent Developments

Comparable Companies

CompanyTypeTickerMkt Cap

Sievert Laryngoscope (Poly Medicure Limited)ListedPOLYMED~6000 Cr

Trivitron Healthcare (Unlisted)Unlisted——

Meril Life Sciences (Unlisted/Pre-IPO)Unlisted——

Sievert Laryngoscope (Poly Medicure Limited)Listed

POLYMED · ~6000 Cr

Frequently Asked Questions

S3V Vascular Technologies Limited is a Mysuru-based MedTech company incorporated in 2011 that develops and manufactures cardiovascular and critical-care medical devices. Its product portfolio includes coronary stents, clot retrieval devices (mechanical thrombectomy), and other interventional cardiology and critical-care products. The company focuses on developing indigenous alternatives to predominantly imported cardiovascular devices.

India imports a large majority of its cardiovascular devices, making the sector a significant foreign exchange outflow. S3V Vascular Technologies aims to develop domestically manufactured alternatives such as coronary stents and clot retrieval devices — directly addressing India's import dependence in a clinically critical product category under the government's push for Atmanirbhar Bharat in medical devices.

About S3V Vascular Technologies Limited

S3V Vascular Technologies Limited is a Mysuru-based MedTech company founded in 2011, developing and manufacturing cardiovascular and critical-care medical devices including coronary stents, clot retrievers, balloon catheters, and aspiration catheters. The company has raised $41.9 million over 8 funding rounds from 147 investors including AM Naik (former L&T Chairman) family office, fund manager Madhusudan Kela, the Technology Development Board of India, and JITO Foundation. S3V serves over 200 healthcare institutions across India with its product portfolio including the 3V Krome Cobalt Chromium coronary stent. In 2024-25, S3V unveiled India's first indigenous balloon-expandable TAVR (Transcatheter Aortic Valve Replacement) system — a high-value structural heart device — pending regulatory approval. Revenue was Rs. 16 Cr in FY2025 with a 5% CAGR, suggesting modest commercial traction despite significant capital raised. A 46% YoY headcount decline noted in mid-2025 raises questions about the company's operational trajectory.

Key Milestones

Incorporated August 9, 2011 in Karnataka (CIN: U33112KA2011PLC059915) — Mysuru; 14+ years old

Cardiovascular + critical-care medical devices; 81 employees (Aug 2025); revenue ₹16 Cr (FY2024-25)

Common questions about unlisted shares

How do I buy S3V Vascular Technologies Limited unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

S3V Vascular Technologies Limited

How settlement works

Get price alerts for S3V Vascular Technologies Limited

Discuss S3V Vascular Technologies Limited

Similar companies

Other ways to invest